Menu
← Oncology Approval Tracker
FDA DECISION ·
Enhertu
fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable or metastatic HER2 IHC 3+ solid tumors previously treated systemically and without satisfactory alternatives.
LAMPGEN ANALYSIS
Why it matters
The antibody–drug conjugate gained a tumor-agnostic indication anchored to strong HER2 expression.
What research teams should watch
Do not substitute other HER2 categories for IHC 3+; make early evaluation of cough or breathlessness part of follow-up.
PRIMARY RECORDS